Factors influencing long-term outcome after kidney transplantation.
TL;DR: Although current immunosuppression regimes are highly efficient in preventing acute rejection, the burden of specific (diabetes, nephrotoxicity) and nonspecific side effects has significant negative long‐term consequences that may well be worse in the future because of the increasing ages of both donors and recipients.
read more
Abstract: Summary
Many factors influence the long-term outcome of kidney transplantation, which is defined very schematically by patient death or renal dysfunction leading to graft loss. The most important of these factors is most likely the quality of the transplant itself, with kidneys from living donors showing a positive impact, while kidneys from expanded criteria donors show deleterious impacts. Various clinicopathological scores exist to predict mid- to long-term outcomes and avoid the transplantation of kidneys displaying inferior results. The key factors related to the recipient include their age as well as disease recurrence, HLA matching, HLA immunization, ethnic background, time on dialysis, and cardiovascular comorbidities. Renal function, defined based on estimated GFR and/or proteinuria values, is a result of all these factors. Delayed graft function has a detrimental long-term impact, as does the level of renal function impairment either in stable condition or in case of progressing dysfunction. Finally, although current immunosuppression regimes are highly efficient in preventing acute rejection, the burden of specific (diabetes, nephrotoxicity) and nonspecific (infection and cancer) side effects has significant negative long-term consequences that may well be worse in the future because of the increasing ages of both donors and recipients. The development of safer immunosuppression strategies is therefore crucial to improve long-term outcomes.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Renal artery embolization—indications, technical approaches and outcomes
Arnaud Muller,Olivier Rouvière +1 more
TL;DR: RAE is increasingly used to treat renal artery aneurysms or symptomatic renal arteriovenous malformations, with a low complication rate as compared with surgical alternatives, and is highlighted as an adjunct in the management of renal disease.
109
Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients—A Prospective, Randomized Study
Elisabet Størset,Anders Åsberg,Morten Skauby,Michael Neely,Stein Bergan,Sara Bremer,Karsten Midtvedt +6 more
TL;DR: The proportion of concentrations per patient within the target range was significantly higher with computerized dosing than with conventional dosing, both in standard risk patients and in high-risk patients.
103
Cardiovascular risk in renal transplant recipients
TL;DR: Aggressive management of traditional cardiovascular risk factors remains the cornerstone of prevention, though there is also a potential role for selecting immunosuppression regimens to minimise additional cardiovascular injury.
Infusion of third-party mesenchymal stromal cells after kidney transplantation: a phase I-II, open-label, clinical study
Pauline Erpicum,Laurent Weekers,Olivier Detry,Catherine Bonvoisin,Marie-Hélène Delbouille,Céline Gregoire,Etienne Baudoux,Alexandra Briquet,Chantal Lechanteur,Gianni Maggipinto,Joan Somja,Hans Pottel,Frédéric Baron,François Jouret,Yves Beguin +14 more
TL;DR: A single infusion of third-party MSC following kidney transplantation appears to be safe, with one cardiac event of unclear relationship to the intervention, and MSC therapy is associated with increased regulatory T cell proportion and with improved early allograft function.
81
References
The natural history of chronic allograft nephropathy.
Brian J. Nankivell,Richard Borrows,Caroline L.-S. Fung,Philip J. O'Connell,Richard D. M. Allen,Jeremy R. Chapman +5 more
TL;DR: Chronic allograft nephropathy represents cumulative and incremental damage to nephrons from time-dependent immunologic and nonimmunologic causes, and was irreversible, resulting in declining renal function and graft failure.
1.9K
Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome
Ch. Legendre,Christoph Licht,Petra Muus,Laurence Greenbaum,Sunil Babu,C. Bedrosian,C. Bingham,David J. Cohen,Y. Delmas,Kenneth W. Douglas,Frank Eitner,Thorsten Feldkamp,Denis Fouque,Richard R. Furman,Osama Gaber,Maria Herthelius,Maryvonne Hourmant,Diana Karpman,Yvon Lebranchu,Christophe Mariat,Jan Menne,Bruno Moulin,Jens Nürnberger,Masayo Ogawa,Giuseppe Remuzzi,T. Richard,Rebecca Sberro-Soussan,B. Severino,Neil S. Sheerin,Antonella Trivelli,L.B. Zimmerhackl,Timothy H.J. Goodship,Chantal Loirat +32 more
TL;DR: Eculizumab inhibited complement-mediated thrombotic microangiopathy and was associated with significant time-dependent improvement in renal function in patients with atypical hemolytic-uremic syndrome and was also associated with improvement in health-related quality of life.
Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence.
Joana Sellarés,D. G. de Freitas,Michael Mengel,Jeff Reeve,Gunilla Einecke,Banu Sis,Luis G. Hidalgo,Konrad S. Famulski,Arthur J. Matas,Philip F. Halloran +9 more
TL;DR: This prospective cohort indicates that many actual failures after indication biopsies manifest phenotypic features of antibody‐mediated or mixed rejection and also underscores the major role of nonadherence.
1.4K
Calcineurin Inhibitor Nephrotoxicity
TL;DR: The authors critically review the current evidence relating systemic blood levels of cyclosporine and tacrolimus to calcineurin inhibitor nephrotoxicity, and summarize the data suggesting that local exposure to cycloporine or tacolimus could be more important than systemic exposure.
1.4K
Machine Perfusion or Cold Storage in Deceased-Donor Kidney Transplantation
Cyril Moers,Jacqueline M. Smits,Mark-Hugo J. Maathuis,Juergen Treckmann,Frank Van Gelder,Bogdan P. Napieralski,Margitta van Kasterop-Kutz,Jaap J. Homan van der Heide,Jean-Paul Squifflet,Ernest van Heurn,Guenter R. Kirste,Axel Rahmel,Henri G. D. Leuvenink,Andreas Paul,Jacques Pirenne,Rutger J. Ploeg +15 more
TL;DR: Hypothermic machine perfusion was associated with a reduced risk of delayed graft function and improved graft survival in the first year after transplantation.
Related Papers (5)
Bertram L. Kasiske,Martin Zeier,Jeremy R. Chapman,Jonathan C. Craig,Henrik Ekberg,Catherine A. Garvey,Michael Green,Vivekanand Jha,Michelle A. Josephson,Bryce A. Kiberd,Henri Kreis,Ruth A. McDonald,John M. Newmann,Gregorio T. Obrador,Flavio Vincenti,Michael Cheung,Amy Earley,Gowri Raman,Samuel A Abariga,Martin Wagner,Ethan M Balk +20 more